Investigating how CD79A regulates B cell activation
CD79A as a molecular switch regulating B cell activation
This study is looking at how a specific protein called CD79A helps control the activation of B cells, which are important for our immune system, to make sure they work properly and don’t cause autoimmune diseases; by understanding this process better, we hope to find new ways to improve treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10858586 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CD79A in B cell activation, which is crucial for immune responses and can lead to autoimmune diseases if not properly regulated. The study examines how biochemical signals from B cell receptors (BCR) are controlled to prevent harmful activation of autoreactive B cells while promoting effective antibody responses. By identifying the mechanisms that activate SHIP-1 in autoreactive B cells, the research aims to uncover new insights into B cell signaling and tolerance. This could lead to better strategies for managing autoimmune conditions and enhancing immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or those who have experienced issues with B cell function.
Not a fit: Patients with non-autoimmune related conditions or those without B cell involvement may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for autoimmune diseases and better vaccine responses.
How similar studies have performed: Previous research has shown success in understanding B cell signaling pathways, making this approach promising but still exploring new aspects.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Getahun, Andrew — University of Colorado Denver
- Study coordinator: Getahun, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.